Table 1:
Baseline patient characteristics
| Placebo (N = 208)* |
IV tPA (N = 172)* |
IV-IA tPA (N = 80)† |
P | |
|---|---|---|---|---|
| Median (iqr) | ||||
| Baseline | ||||
| Age | 66 (58–72) | 69 (59–74) | 65 (54.5–75) | .229 |
| Gender (% female) | 44 | 42 | 50 | .513 |
| bNIHSS | 17 (13–22) | 17 (14–21) | 18 (14–21) | .857 |
| Glucose (mM) | 7.0 (6.0–8.75) | 6.9 (5.8–9.5) | 6.2 (5.6–7.3) | .0098 |
| bASPECTS | 8 (6–10) | 8 (6–10) | 7 (4–9) | .0003 |
| bASPECTS > 7 (%) | 62.5 | 57.0 | 37.5 | .001 |
| Onset-to-treat time (min) | 108.5 (89–150) | 90 (88–149) | 140 (110–158) | <.001 |
| Outcomes | ||||
| Death (%) | 24 | 20 | 16 | .361 |
| mRS 0–1 (%) | 18 | 33 | 30 | .002 |
| mRS 0–2 (%) | 28 | 40 | 43 | .016 |
| NIHSS 0–1 (%) | 15 | 25 | 28 | .013 |
| sICH (%) | 0.96 | 5.2 | 6.3 | .014 |
Note:—tPA indicates tissue plasminogen activator; iqr, interquartile range; bNIHSS, baseline National Institutes of Health Stroke score; ASPECTS, Alberta Stroke Program Early CT score; bASPECTS, baseline ASPECT score; mRS, modified Rankin Scale; sICH, symptomatic intracerebral hemorrhage.
*
From a subset of the NINDS tPA Stroke Study.
†
From the IMS-1 Trial.